Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
Phase 1 Terminated
1 enrolled
PIPSeN
Phase 2 Terminated
180 enrolled
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
Phase 3 Terminated
358 enrolled
AMTEC IIT: Phase 2 Multiarm Study in TNBC
Phase 2 Terminated
24 enrolled 16 charts
FAB
Phase 2 Terminated
27 enrolled
Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors
Phase 1 Terminated
13 enrolled
POLAR
Phase 1 Terminated
26 enrolled 14 charts
Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences
Phase 1 Terminated
3 enrolled
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
82 enrolled
ATTACC
Phase 1/2 Terminated
156 enrolled 19 charts
Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
Phase 2 Terminated
6 enrolled 10 charts
337
Phase 2 Terminated
1 enrolled 8 charts
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
Phase 1 Terminated
221 enrolled
CORONADO CLL
Phase 1/2 Terminated
5 enrolled 13 charts
Pembrolizumab and Olaparib in Cervical Cancer Patients
Phase 2 Terminated
8 enrolled 13 charts
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase 1/2 Terminated
19 enrolled 11 charts
Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer
Phase 2 Terminated
4 enrolled 5 charts
Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
Phase 2 Terminated
4 enrolled 11 charts
Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma
Phase 2 Terminated
2 enrolled 9 charts
REVOCAN
Phase 1/2 Terminated
13 enrolled
Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer
Phase 2 Terminated
3 enrolled 9 charts
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
Phase 1/2 Terminated
7 enrolled
A Study of Olaparib and Durvalumab in Prostate Cancer
Phase 2 Terminated
5 enrolled 4 charts
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
Phase 1 Terminated
24 enrolled
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1 Terminated
2 enrolled
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
Phase 2 Terminated
9 enrolled 4 charts
TAILOR
Phase NA Terminated
3 enrolled
NOBROLA
Phase 2 Terminated
7 enrolled
OPHELIA
Phase 2 Terminated
5 enrolled
OLAPCO
Phase 2 Terminated
67 enrolled 10 charts
AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours
Phase 1 Terminated
44 enrolled
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers
Phase 1 Terminated
3 enrolled
Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy
Phase 2 Terminated
140 enrolled
Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer
Phase 2 Terminated
2 enrolled 4 charts
A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer
Phase 1 Terminated
15 enrolled 8 charts